We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Hemosonics - A Stago Company

HemoSonics is a medical device company developing a point-of-care diagnostic platform to guide the management of crit... read more Featured Products: More products

Download Mobile App




Next-Gen POC Whole Blood Hemostasis System Recognizes Specific Needs of EDs and ORs

By LabMedica International staff writers
Posted on 01 Dec 2022
Print article
Image: Quantra Hemostasis Analyzer (Photo courtesy of HemoSonics)
Image: Quantra Hemostasis Analyzer (Photo courtesy of HemoSonics)

Current hemostatic tests provide only a subset of needed information, or take too long to be useful in critical bleeding situations, forcing clinicians to use iterative transfusion protocols that do not account for the patient’s actual coagulation status. This approach leads to over-transfusion and transfusion of inappropriate products. Up to 60% of red blood cell (RBC) transfusions lack clinical justification. Further, blood products are costly, making up about 1-2% of a hospital’s budget. Hospitals around the world are thus seeking ways to reduce their transfusion rates to improve outcomes and reduce costs.

Now, a next-generation point-of-care (POC) hemostasis system leverages innovative medical-grade ultrasound technology to measure the coagulation properties of a whole blood sample. The system enables clinicians to deliver patient-centered coagulation therapy that improves care and optimizes blood product usage. With its rapid results, ease of operation, and dials screen for straightforward interpretation, it is the only whole blood hemostasis testing system specifically cleared for use in POC settings, such as operating rooms, emergency departments, and intensive care units.

HemoSonics, LLC’s (Durham, NC, USA) innovative Quantra hemostasis analyzer platform, based on patented SEER sonorheometry, enables fully automated, rapid point-of-care viscoelastic testing and gives physicians the results they need at the POC to make more informed decisions. SEER uses state-of-the-art ultrasound technology to measure clot stiffness (shear modulus of elasticity) over time using ultrasound-induced resonance. The Quantra system’s innovative closed-cartridge design requires no open-tube blood manipulation after sample collection and it automatically runs internal QC every eight hours and with every test. The Quantra system’s innovative ultrasound technology, proprietary closed-cartridge design, unparalleled ease of use, and ease of interpretation make it uniquely suited for use in critical or emergency care settings.

HemoSonics has now received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the Quantra Hemostasis System with QStat Cartridge. The FDA clearance of the QStat Cartridge expands the Quantra System's indications for use to include trauma, and liver transplantation procedures. The QStat Cartridge assay, in addition to the System's already established QPlus Cartridge assay, increases Quantra's overall diagnostic capabilities to now cover the broadest range of clinical indications of any point-of-care hemostasis analyzer available in the U.S. market today.

"The Quantra Hemostasis System with QStat Cartridge is breaking new ground and leading innovation in the point-of-care and laboratory-based whole blood hemostasis testing market. Today's clearance significantly expands the clinical indications of the Quantra System, creating the greatest opportunity to address the critical unmet clinical needs of our healthcare provider partners and the patients that we serve," said Robert Roda, President, and Chief Executive Officer of HemoSonics.

"Point-of-care data is the answer to PBM-guided patient decisions. It is a triple win; Patients get improved outcomes, public health is improved, and cost savings are achieved," said Dr. Bruce Spiess, Medical Director of HemoSonics. "The Quantra Hemostasis System with QStat and QPlus Cartridges will assist more clinicians in determining which specific blood products are needed to rapidly treat individual patients. It has the potential to positively impact patient outcomes for hundreds of thousands of trauma patients and thousands of liver transplant recipients each year by optimizing blood product usage and conserving critically low blood supplies."

Related Links:
HemoSonics, LLC

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
New
CMV QC
Inactivated Cytomegalovirus High Control
New
Vaginal pH Screening Kit
Vaginal pH Screening Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The lateral flow test could detect prostate cancer more quickly and with greater accuracy (Photo courtesy of Valley Diagnostics)

Groundbreaking Test Could Detect Prostate Cancer Within Minutes Via Urine Sample

In the UK, over 52,000 men are diagnosed with prostate cancer annually, with up to one-quarter of these cases identified at a later stage, requiring more intensive treatments. The cost to the NHS for these... Read more

Hematology

view channel
Image: The new test could improve specialist transplant and transfusion practice as well as blood banking (Photo courtesy of NHS Blood and Transplant)

New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape

The release of oxygen by red blood cells is a critical process for oxygenating the body's tissues, including organs and muscles, particularly in individuals receiving large blood transfusions.... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: The iFAST reader scans 5000 individual bacteria with each sample analyzed in less than a minute (Photo courtesy of iFAST)

High-Throughput AST System Uses Microchip Technology to Rapidly Analyze Bacterial Samples

Bacteria are becoming increasingly resistant to antibiotics, with resistance levels ranging from 20% to 98%, and these levels are unpredictable. Currently, antimicrobial susceptibility testing (AST) takes... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.